A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient

被引:23
作者
Maguire, Michelle [2 ]
Franz, Thaddeus [3 ]
Hains, David S. [1 ,4 ]
机构
[1] Nationwide Childrens Hosp, Div Pediat Nephrol, Columbus, OH 43206 USA
[2] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[3] Nationwide Childrens Hosp, Dept Pharm, Columbus, OH 43206 USA
[4] Nationwide Childrens Hosp, Ctr Clin & Translat Res, Res Inst, Columbus, OH 43206 USA
关键词
tacrolimus; proton pump inhibitors; drug interaction; pediatric renal transplantation; CYP; 2C19; pharmacogenetics; CYTOCHROME-P450; ACTIVITIES; DRUG-INTERACTIONS; PHARMACOKINETICS; OMEPRAZOLE; AZITHROMYCIN; LANSOPRAZOLE; RABEPRAZOLE; CYP2C19; PHARMACODYNAMICS; POLYMORPHISMS;
D O I
10.1111/j.1399-3046.2011.01559.x
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Maguire M, Franz T, Hains DS. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. ?Pediatr Transplantation 2011. (c) 2011 John Wiley & Sons A/S. Abstract: The shared metabolism of PPIs and tacrolimus through the CYP enzyme system has been associated with clinically significant drug interactions, especially in patients who are classified as CYP 2C19 PMs. However, existing data are conflicting, indicating that a single mechanism does not account for all interactions. A drug interaction between tacrolimus and omeprazole, esomeprazole, but not lansoprazole, occurred in an 18-yr-old female kidney transplant recipient classified as a CYP 2C19 extensive (normal) metabolizer. This case suggests that further research is needed to establish the definitive mechanism of this potentially serious drugdrug interaction. Physicians prescribing PPIs in organ transplant recipients with tacrolimus immunosuppression should consider close pharmacokinetic monitoring of tacrolimus when starting or switching a PPI.
引用
收藏
页码:E217 / E220
页数:4
相关论文
共 21 条
  • [1] COMPARISON OF THE EFFECTS OF THE NEW AZALIDE ANTIBIOTIC, AZITHROMYCIN, AND ERYTHROMYCIN ESTOLATE ON RAT-LIVER CYTOCHROME-P-450
    AMACHER, DE
    SCHOMAKER, SJ
    RETSEMA, JA
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (06) : 1186 - 1190
  • [2] IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM
    ANDERSSON, T
    MINERS, JO
    VERONESE, ME
    TASSANEEYAKUL, W
    TASSANEEYAKUL, W
    MEYER, UA
    BIRKETT, DJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) : 521 - 530
  • [3] Mechanisms of clinically relevant drug interactions associated with tacrolimus
    Christians, U
    Jacobsen, W
    Benet, LZ
    Lampen, A
    [J]. CLINICAL PHARMACOKINETICS, 2002, 41 (11) : 813 - 851
  • [4] Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
    Hesselink, DA
    van Schaik, RHN
    van der Heiden, IP
    van der Werf, M
    Gregoor, PJHS
    Lindemans, J
    Weimar, W
    van Gelder, T
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) : 245 - 254
  • [5] Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients
    Hosohata, Keiko
    Masuda, Satohiro
    Katsura, Toshiya
    Takada, Yasutsugu
    Kaido, Toshimi
    Ogura, Yasuhiro
    Oike, Fumitaka
    Egawa, Hiroto
    Uemoto, Shinji
    Inui, Ken-ichi
    [J]. DRUG METABOLISM AND DISPOSITION, 2009, 37 (04) : 821 - 826
  • [6] Ishizaki T, 1999, ALIMENT PHARM THERAP, V13, P27
  • [7] Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations
    Itagaki, F
    Homma, M
    Yuzawa, K
    Nishimura, M
    Naito, S
    Ueda, N
    Ohkohchi, N
    Kohda, Y
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (08) : 1055 - 1059
  • [8] Katsakiori PF, 2010, THER CLIN RISK MANAG, V6, P265
  • [9] Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)
    Klotz, Ulrich
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (01) : 1 - 2
  • [10] Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
    Li, XQ
    Andersson, TB
    Ahlström, M
    Weidolf, L
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) : 821 - 827